This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Biohaven Pharmaceutical Holding Management

Management criteria checks 2/4

Key information

Vlad Coric

Chief executive officer

US$10.9m

Total compensation

CEO salary percentage	6.9%
CEO tenure	7yrs
CEO ownership	1.3%
Management average tenure	3.5yrs
Board average tenure	4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Vlad Coric's remuneration changed compared to Biohaven Pharmaceutical Holding's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2022	n/a	n/a	-US$1b
Mar 31 2022	n/a	n/a	-US$791m
Dec 31 2021	US$11m	US$750k	-US$847m
Sep 30 2021	n/a	n/a	-US$865m
Jun 30 2021	n/a	n/a	-US$889m
Mar 31 2021	n/a	n/a	-US$859m
Dec 31 2020	US$1m	US$622k	-US$767m
Sep 30 2020	n/a	n/a	-US$698m
Jun 30 2020	n/a	n/a	-US$609m
Mar 31 2020	n/a	n/a	-US$639m
Dec 31 2019	US$7m	US$550k	-US$529m
Sep 30 2019	n/a	n/a	-US$434m
Jun 30 2019	n/a	n/a	-US$390m
Mar 31 2019	n/a	n/a	-US$218m
Dec 31 2018	US$5m	US$500k	-US$241m
Sep 30 2018	n/a	n/a	-US$213m
Jun 30 2018	n/a	n/a	-US$195m
Mar 31 2018	n/a	n/a	-US$202m
Dec 31 2017	US$4m	US$421k	-US$139m
Sep 30 2017	n/a	n/a	-US$138m
Jun 30 2017	n/a	n/a	-US$123m
Mar 31 2017	n/a	n/a	-US$83m
Dec 31 2016	US$784k	US$350k	-US$64m

Compensation vs Market: Vlad's total compensation ($USD10.92M) is above average for companies of similar size in the German market ($USD5.34M).

Compensation vs Earnings: Vlad's compensation has increased whilst the company is unprofitable.

CEO

Vlad Coric (51 yo)

7yrs

Tenure

US$10,924,824

Compensation

Dr. Vladimir Coric, also known as Vlad, M.D., is Director at Pyramid Biosciences Inc. since August 2020. He has been Independent Director of Social Capital Suvretta Holdings Corp. I since June 29, 2021. He...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Vladimir Coric	Chairman of the Board	7yrs	US$10.92m	1.29% $ 141.8m
Matthew Buten	Chief Financial Officer	less than a year	US$6.03m	0.0086% $ 949.2k
Kimberly Gentile	Senior Vice President of Clinical Operations	5.8yrs	US$3.76m	0.016% $ 1.8m
Elyse Stock	Chief Medical Officer	5.3yrs	US$3.88m	0.023% $ 2.5m
William Jones	Chief Commercial Officer of Migraine & Common Diseases	3.5yrs	US$4.69m	0.020% $ 2.2m
Matthew DeLawder	Director of Accounting	3.8yrs	no data	no data
George Clark	VP & Chief Accounting Officer	1.2yrs	no data	0.0057% $ 625.1k
Charles Conway	Chief Scientific Officer	5.8yrs	US$2.79m	0% $ 0
Wendy Goss	Executive Administrative Assistant	no data	no data	no data
Clifford Bechtold	President & GM of Biohaven Ireland and Chief Compliance Officer	1.4yrs	no data	no data
Warren Volles	General Counsel & Chief Legal Officer	less than a year	no data	no data
Jenny Strauss	Manager of Medical Information & Communication	2.8yrs	no data	no data

3.5yrs

Average Tenure

58yo

Average Age

Experienced Management: 2VN's management team is considered experienced (3.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Vladimir Coric	Chairman of the Board	7yrs	US$10.92m	1.29% $ 141.8m
Douglas Gray	Corporate Secretary & Director	less than a year	no data	no data
John Childs	Independent Director	8.8yrs	US$560.01k	4.25% $ 466.4m
Julia Gregory	Independent Director	5.2yrs	US$560.06k	0% $ 0
Robert Hugin	Independent Director	2.3yrs	US$990.02k	0.0041% $ 446.0k
Gregory Bailey	Independent Director	8.8yrs	US$541.83k	3.61% $ 397.0m
Michael Heffernan	Lead Independent Director	2.8yrs	US$987.80k	0.041% $ 4.5m
Maurizio Fava	Member of Scientific Advisory Board	no data	no data	no data
Richard B. Lipton	Chairman of Scientific Advisory Board	no data	no data	no data
John Krystal	Member of Scientific Advisory Board	no data	no data	no data
Kishan Mehta	Director	1.3yrs	US$741.91k	0.015% $ 1.6m
Gerard Sanacora	Member of Scientific Advisory Board	no data	no data	no data

4.0yrs

Average Tenure

66yo

Average Age

Experienced Board: 2VN's board of directors are considered experienced (4 years average tenure).

This company listing is no longer active

Biohaven Pharmaceutical Holding Management

Management criteria checks 2/4

Key information

Recent management updates

Independent Director recently bought €5.6m worth of stock

Biohaven Pharmaceutical Holding Company Ltd. Appoints Irina Antonijevic, M.D., Ph.D., as A Director, Effective May 1, 2022

Independent Chairman of the Board recently sold €2.5m worth of stock

Independent Director recently bought €533k worth of stock

Independent Director recently bought €840k worth of stock

Independent Director recently bought €705k worth of stock

Recent updates

Biohaven Pharmaceutical Holding Company Ltd. completed the Spin-Off of Biohaven Ltd. (NYSE:BHVN).

Pfizer Inc. (NYSE:PFE) completed the acquisition of the remaining 97.1% stake in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) from BlackRock, Inc. (NYSE:BLK) and others.

Biohaven Pharmaceutical Holding Company Ltd. Provides Update from Pivotal Phase 2/3 Trial with Verdiperstat in Amyotrophic Lateral Sclerosis (Healy Als Platform Trial)

No longer forecast to breakeven

Independent Director recently bought €5.6m worth of stock

Second quarter 2022 earnings released: US$6.21 loss per share (vs US$3.24 loss in 2Q 2021)

No longer forecast to breakeven

Biohaven Pharmaceutical Holding Company Ltd. Commences Enrollment in Phase 3 Clinical Trial Assessing Efficacy and Safety of Taldefgrobep Alfa in Spinal Muscle Atrophy

US FDA Accepts for Review Biohaven's New Drug Application filing of Intranasal Zavegepant for the Acute Treatment of Migraine

Pfizer Inc. (NYSE:PFE) entered into an agreement to acquire the remaining 97.1% stake in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) for $10.4 billion.

First quarter 2022 earnings released: US$2.97 loss per share (vs US$4.27 loss in 1Q 2021)

Biohaven Pharmaceutical Holding Company Ltd. to Report Q1, 2022 Results on May 10, 2022

Biohaven Pharmaceutical Holding Company Ltd. Appoints Irina Antonijevic, M.D., Ph.D., as A Director, Effective May 1, 2022

Biohaven Pharmaceutical Holding Company Ltd. Announces Publication of New Real-World Research Showing that as Migraine-Related Disability Increases

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) entered into a definitive agreement to acquire Channel Biosciences, LLC from Knopp Biosciences LLC for $1.2 billion.

Biohaven Pharmaceutical Holding Company Ltd. Enrolls First Patient in Phase 2/3 Sinusitis Trial of Nurtec® ODT

Biohaven Pharmaceutical Holding Company Ltd. to Report Q4, 2021 Results on Feb 25, 2022

Forecast to breakeven in 2024

Biohaven Announces Nurtec® Odt Receives First Global Approval Outside the U.S. for Prevention of Migraine

Independent Chairman of the Board recently sold €2.5m worth of stock

No longer forecast to breakeven

Independent Director recently bought €533k worth of stock

Third quarter 2021 earnings released: US$2.63 loss per share (vs US$3.27 loss in 3Q 2020)

Forecast to breakeven in 2023

Biohaven Pharmaceutical Holding Company Ltd. Provides Update on Phase 3 Trial and Multiple System Atrophy (MSA) Program

Second quarter 2021 earnings released: US$3.24 loss per share (vs US$3.08 loss in 2Q 2020)

Biohaven Pharmaceutical Holding Company Ltd. Showcases CGRP-Antagonist Franchise Data Including Nurtec ODT (Rimegepant), Now Approved to Treat and Prevent Migraine Attacks, and Zavegepant with 19 Presentations

Biohaven Pharmaceutical Holding Company Ltd. Announces U.S. Food and Drug Administration Approval for NURTEC® ODT for the Preventive Treatment of Migraine

First quarter 2021 earnings released: US$4.21 loss per share (vs US$3.07 loss in 1Q 2020)

Independent Director recently bought €840k worth of stock

Biohaven Pharmaceutical Holding Company Ltd. has completed a Follow-on Equity Offering in the amount of $204.167084 million.

Biohaven's NURTEC® ODT Approves in Israel for Acute Treatment of Migraine

Independent Director recently bought €705k worth of stock

Revenue beats expectations

Biohaven's BHV-1200, A Multimodal Antibody Therapy Enhancer (MATE), Demonstrates Effective Neutralization Of Multiple Strains Of COVID-19

New 90-day low: €63.50

Biohaven Pharmaceuticals Signs Cody Ware as Driver for Nurtec® Odt Chevrolet for the 2021 NASCAR Cup Series Season

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) completed the acquisition of remaining 58% stake in Kleo Pharmaceuticals, Inc from PeptiDream Inc. (TSE:4587) and others.

Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder

Biohaven Pharmaceutical Holding Company Ltd Announces Positive Results from Phase 3 Clinical Trial of Rimegepant for the Preventive Treatment of Migraine in Adults

Sosei Group Corporation and Biohaven Pharmaceutical Holding Company Ltd. Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio

Independent Director recently bought €379k worth of stock

Biohaven Pharmaceutical Holding Company Ltd. and Weill Cornell Medicine Collaborate to Initiate Proof of Concept Trial with CGRP Receptor Antagonist in Plaque Psoriasis

Biohaven Pharmaceuticals Inaugural Partner of National Ataxia Foundation's Drug Development Collaborative

New 90-day high: €75.50

Biohaven Pharmaceutical Holding Company Ltd. to Report Q3, 2020 Results on Nov 09, 2020

New 90-day high: €66.50

U.S. FDA Accepts Biohaven's Supplemental New Drug Application (sNDA) Of NURTEC™ ODT For The Preventive Treatment Of Migraine

Independent Director recently bought €168k worth of stock

Independent Director recently bought €333k worth of stock

Biohaven Pharmaceutical Holding Company Ltd. to Report Q2, 2020 Results on Aug 10, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age